Background Ureteral stents are commonly used to ensure adequate drainage of the upper urinary tract in the presence, or anticipated occurrence, of ureteral obstruction. However, stent-related symptoms are frequent and represent a significant source of morbidity. Although several pharmacological treatment options are currently available, symptom relief remains often incomplete. In an effort to achieve better control of stent-related symptoms, we evaluated the efficacy of dose doubling in two commonly used drug combinations that have demonstrated symptomatic benefits in this context.
Hefnawy et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: